Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545947 · ClinicalTrials.gov registry record · Phase 1
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT01545947 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 76 participants.
The verdict
NCT01545947, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each combination in order to evaluate their effects in future clinical trials for advanced non-small cell lung cancer.
Interventions
- DRUG CC-223, erlotinib
- DRUG CC-223, oral azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2012-05-01 |
| Est. Completion | 2014-12-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01545947
The ClinicalTrials.gov registry entry for NCT01545947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CC-223, erlotinib is the first listed.
NCT01545947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01545947 about?
NCT01545947 is a clinical study titled "Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer". The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each combination in order to evaluate their effects in future clinical trials...
What is the current status of trial NCT01545947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2012-05-01. Estimated completion is 2014-12-11.
What interventions are being tested in trial NCT01545947?
The interventions under investigation include: CC-223, erlotinib (DRUG), CC-223, oral azacitidine (DRUG).
Who is sponsoring clinical trial NCT01545947?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.